Drug intelligence / Profile preview

AKST4290 + aflibercept

Development stage: Unknown
Lead developer: Alkahest
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravitreal, Oral

Overview

AKST4290 + aflibercept is a combination therapy consisting of AKST4290, a highly selective and potent small molecule CCR3 antagonist administered orally, and aflibercept, an established anti-VEGF therapy administered via intravitreal injection. This combination is being investigated for the treatment of neovascular age-related macular degeneration (nAMD), with the goal of reducing inflammation and neovascularization while potentially decreasing the treatment burden of frequent intravitreal injections.

Targets

VEGFB (Vascular endothelial growth factor B)CCR3 (C-C chemokine receptor type 3)VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)

Beyond the preview

Go deeper on AKST4290 + aflibercept.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AKST4290 + aflibercept.

Explore the full profile